Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Healthcare remains a cornerstone for long-term investors, but choosing between a pure-play drugmaker and a diversified conglomerate is difficult. Is Bristol-Myers Squibb (NYSE:BMY) or Johnson & Johnson (NYSE:JNJ) the better choice today?

Bristol-Myers Squibb focuses on developing innovative medicines for serious diseases, while Johnson & Johnson combines a pharmaceutical powerhouse with a massive medical technology division. Both companies face unique regulatory hurdles and patent cycles, making their outlooks a study in risk versus stability.

The case for Bristol-Myers Squibb

Bristol-Myers Squibb focuses on specialized biopharmaceutical products, particularly in the fields of oncology, hematology, and cardiovascular health. The company distributes its medicines through wholesalers and specialty pharmacies, while also utilizing direct-to-patient offerings. Key partnerships with companies like BioNTech (NASDAQ:BNTX) and the U.S. Government help support its global reach and development efforts.

In FY 2025, revenue reached nearly $48.2 billion, which was a slight decrease of roughly 0.2% compared to the prior year. The company reported a net income of approximately $7.1 billion for the same period. This marked a significant recovery for the business, following a substantial net loss reported in the previous fiscal year.

Bristol has total cash of $11 billion, with over $45 billion in debt. It's profit margin is 18.8%, while it's 12-month trailing operating margin is 34.4%.

The case for Johnson & Johnson

Johnson & Johnson operates as a diversified healthcare giant through its Innovative Medicine and MedTech segments. It provides treatments for immunology and oncology, while its medical device business serves hospitals and healthcare professionals globally.

In FY 2025, revenue reached nearly $94.2 billion, which was an increase of approximately 6% over the prior year. The company reported a robust net income of close to $26.8 billion for the full fiscal year.

Johnson & Johnson has cash of $20.7 billion, with debt of more than $49 billion. Its total debt-to-equity ratio is 57.7%. It's profit margin is 16.2%, while its operating margin over a 12-month trailing period is 25%.

Risk profile comparison

Bristol-Myers Squibb faces intense pricing pressure from the Inflation Reduction Act, which targets key products like Eliquis and Pomalyst for government-negotiated pricing. Patent expirations for major drugs and legal challenges from generic manufacturers add further uncertainty to future revenue streams. Additionally, the company is managing a reinstated $6.7 billion lawsuit related to its Celgene acquisition and the complex integration of several recent acquisitions.

Johnson & Johnson is also navigating healthcare reforms that impact pricing for core drugs like XARELTO and STELARA. The company faces ongoing patent challenges from biosimilar competitors and is currently managing the execution risks and costs of separating its Orthopaedics business. Furthermore, the company deals with significant litigation involving talc-containing products and competition from Pfizer (NYSE:PFE) and Merck (NYSE:MRK).

Valuation comparison

Bristol-Myers Squibb appears cheaper on a multiple basis, while Johnson & Johnson commands a higher price for its stability and diversified revenue streams.

Which stock would I buy in 2026?

These two stocks can serve different purposes for a portfolio, but there's one I would pick over the other. With Bristol, you're getting a solid income from its dividend, which currently yields 4.1%. The catch, however, is that you are also accepting the risk that it may not find new hits in its drug pipeline to counter some of the patent cliffs it faces. It looks like it's on the right track, as the revenues from its growth portfolio climbed 15% in the second quarter of 2026 to $7.6 billion. Still, it has to maintain momentum, and developing new drugs is costly, time-consuming, and fraught with challenges.

Johnson & Johnson, in comparison, is firing on all cylinders. After spinning off its sluggish consumer healthcare division in August 2023, it has been able to focus more on its pharmaceutical and medical device products. For the third quarter of 2026, Johnson & Johnson just reported sales of $25.4 billion, a 5.9% increase from the prior-year period.

Looking at the two companies, the revenue opportunities for Johnson & Johnson are simply larger, as highlighted by the company's 2025 revenue. While Bristol reported about $48 billion, Johnson & Johnson's was nearly double at over $94 billion. Also, while Johnson & Johnson's dividend yield of 2.1% may be lower than Bristol's, Johnson & Johnson is also a Dividend King, having increased its dividend payout for 64 consecutive years. That means, even if its dividend payout yields less, it has still been a reliable payer, a bonus when choosing between the two companies.

Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BioNTech Se, Bristol Myers Squibb, Merck, and Pfizer. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.